Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Long-term physical activity in people with multiple sclerosis: exploring expert views on facilitators and barriers.

Riemann-Lorenz K, Wienert J, Streber R, Motl RW, Coote S, Heesen C.

Disabil Rehabil. 2019 Mar 23:1-13. doi: 10.1080/09638288.2019.1584253. [Epub ahead of print]

PMID:
30907162
2.

Impairment and restrictions in possibly benign multiple sclerosis.

Schaefer LM, Poettgen J, Fischer A, Gold S, Stellmann JP, Heesen C.

Brain Behav. 2019 Mar 18:e01259. doi: 10.1002/brb3.1259. [Epub ahead of print]

3.

Development of Cortical Lesion Volumes on Double Inversion Recovery MRI in Patients With Relapse-Onset Multiple Sclerosis.

Faizy TD, Broocks G, Thaler C, Rauch G, Gebert P, Stürner KH, Flottmann F, Leischner H, Kniep HC, Stellmann JP, Heesen C, Fiehler J, Gellißen S, Hanning U.

Front Neurol. 2019 Feb 22;10:133. doi: 10.3389/fneur.2019.00133. eCollection 2019.

4.

Emotions towards magnetic resonance imaging in people with multiple sclerosis.

Engels K, Schiffmann I, Weierstall R, Rahn AC, Daubmann A, Pust G, Chard D, Lukas C, Scheiderbauer J, Stellmann JP, Heesen C.

Acta Neurol Scand. 2019 Feb 25. doi: 10.1111/ane.13082. [Epub ahead of print]

PMID:
30802931
5.

Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis.

Stork L, Brück W, von Gottberg P, Pulkowski U, Kirsten F, Glatzel M, Rauer S, Scheibe F, Radbruch H, Hammer E, Stürner KH, Kaulen B, Heesen C, Hoffmann F, Brock S, Pawlitzki M, Bopp T, Metz I.

Mult Scler. 2019 Jan 18:1352458518819098. doi: 10.1177/1352458518819098. [Epub ahead of print]

PMID:
30657420
6.

Benefit evaluation in multiple sclerosis relapse treatment from the patients' perspective - Development and validation of a new questionnaire.

Beckmann H, Augustin M, Heesen C, Poettgen J, Blome C.

Mult Scler Relat Disord. 2019 Feb;28:256-261. doi: 10.1016/j.msard.2018.12.021. Epub 2018 Dec 17.

PMID:
30639826
7.

Short-term interval aerobic exercise training does not improve memory functioning in relapsing-remitting multiple sclerosis-a randomized controlled trial.

Baquet L, Hasselmann H, Patra S, Stellmann JP, Vettorazzi E, Engel AK, Rosenkranz SC, Poettgen J, Gold SM, Schulz KH, Heesen C.

PeerJ. 2018 Dec 12;6:e6037. doi: 10.7717/peerj.6037. eCollection 2018.

8.

Guest Editorial: Shared Decision Making in Managing Multiple Sclerosis: Revisiting the Research Agenda.

Heesen C, Rahn AC.

Int J MS Care. 2018 Nov-Dec;20(6):v-vi. doi: 10.7224/1537-2073.2018-098. No abstract available.

9.

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Bergh FT, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H, Salmen A; German Competence Network Multiple Sclerosis (KKNMS).

J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y. Epub 2018 Dec 4.

10.

Risk knowledge of people with relapsing-remitting multiple sclerosis - Results of an international survey.

Giordano A, Liethmann K, Köpke S, Poettgen J, Rahn AC, Drulovic J, Beckmann Y, Sastre-Garriga J, Galea I, Heerings M, Jongen PJ, Vettorazzi E, Solari A, Heesen C; AutoMS group.

PLoS One. 2018 Nov 29;13(11):e0208004. doi: 10.1371/journal.pone.0208004. eCollection 2018.

11.

Prognostic information for people with MS: Impossible or inevitable?

Heesen C, Scalfari A, Galea I.

Mult Scler. 2018 Oct 16:1352458518807101. doi: 10.1177/1352458518807101. [Epub ahead of print]

PMID:
30325713
12.

Information provision for people with multiple sclerosis.

Köpke S, Solari A, Rahn A, Khan F, Heesen C, Giordano A.

Cochrane Database Syst Rev. 2018 Oct 14;10:CD008757. doi: 10.1002/14651858.CD008757.pub3.

PMID:
30317542
13.

Magnetic resonance imaging as a prognostic disability marker in clinically isolated syndrome: A systematic review.

Rahn AC, Köpke S, Stellmann JP, Schiffmann I, Lukas C, Chard D, Heesen C.

Acta Neurol Scand. 2019 Jan;139(1):18-32. doi: 10.1111/ane.13010. Epub 2018 Sep 6.

PMID:
30091223
14.

Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring.

Stoessel D, Stellmann JP, Willing A, Behrens B, Rosenkranz SC, Hodecker SC, Stürner KH, Reinhardt S, Fleischer S, Deuschle C, Maetzler W, Berg D, Heesen C, Walther D, Schauer N, Friese MA, Pless O.

Front Hum Neurosci. 2018 Jun 4;12:226. doi: 10.3389/fnhum.2018.00226. eCollection 2018.

15.

Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis.

Pöttgen J, Moss-Morris R, Wendebourg JM, Feddersen L, Lau S, Köpke S, Meyer B, Friede T, Penner IK, Heesen C, Gold SM.

J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):970-976. doi: 10.1136/jnnp-2017-317463. Epub 2018 Mar 16.

PMID:
29549193
16.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

17.

Sexual dysfunctions in MS in relation to neuropsychiatric aspects and its psychological treatment: A scoping review.

Pöttgen J, Rose A, van de Vis W, Engelbrecht J, Pirard M, Lau S, Heesen C, Köpke S; RiMS Special Interest Group Psychology and Neuropsychology.

PLoS One. 2018 Feb 27;13(2):e0193381. doi: 10.1371/journal.pone.0193381. eCollection 2018. Review.

18.

Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?

Schiffmann I, Scheiderbauer J, Riemann-Lorenz K, Heesen C.

Mult Scler. 2018 Sep;24(10):1387-1388. doi: 10.1177/1352458517749895. Epub 2018 Jan 8. No abstract available.

PMID:
29308975
19.

A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial).

Stürner KH, Stellmann JP, Dörr J, Paul F, Friede T, Schammler S, Reinhardt S, Gellissen S, Weissflog G, Faizy TD, Werz O, Fleischer S, Vaas LAI, Herrmann F, Pless O, Martin R, Heesen C.

J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):330-338. doi: 10.1136/jnnp-2017-317101. Epub 2017 Dec 16.

PMID:
29248894
20.

Perceptions on the value of bodily functions in multiple sclerosis.

Heesen C, Haase R, Melzig S, Poettgen J, Berghoff M, Paul F, Zettl U, Marziniak M, Angstwurm K, Kern R, Ziemssen T, Stellmann JP.

Acta Neurol Scand. 2018 Mar;137(3):356-362. doi: 10.1111/ane.12881. Epub 2017 Dec 3.

PMID:
29205262
21.

The use of multiparametric quantitative magnetic resonance imaging for evaluating visually assigned lesion groups in patients with multiple sclerosis.

Thaler C, Faizy TD, Sedlacik J, Bester M, Stellmann JP, Heesen C, Fiehler J, Siemonsen S.

J Neurol. 2018 Jan;265(1):127-133. doi: 10.1007/s00415-017-8683-9. Epub 2017 Nov 20.

PMID:
29159467
22.

What should a person with relapsing-remitting multiple sclerosis know? - Focus group and survey data of a risk knowledge questionnaire (RIKNO 2.0).

Heesen C, Pöttgen J, Rahn AC, Liethmann K, Kasper J, Vahter L, Drulovic J, Van Nunen A, Wilkie D, Beckmann Y, Paul F, Köpke S, Giordano A, Solari A; AutoMS-group.

Mult Scler Relat Disord. 2017 Nov;18:186-195. doi: 10.1016/j.msard.2017.09.020. Epub 2017 Sep 21.

PMID:
29141808
23.

Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.

Akbulak RÖ, Rosenkranz SC, Schaeffer BN, Pinnschmidt HO, Willems S, Heesen C, Hoffmann BA.

Mult Scler Relat Disord. 2018 Jan;19:44-49. doi: 10.1016/j.msard.2017.10.020. Epub 2017 Nov 2.

PMID:
29127856
24.

Aberrant peak lactate response in MS.

Schlüter K, Maier J, Patra S, Gold SM, Heesen C, Schulz KH.

NeuroRehabilitation. 2017;41(4):811-822. doi: 10.3233/NRE-172182.

PMID:
29036843
25.

Low clinical conversion rate in clinically isolated syndrome patients - diagnostic benefit of McDonald 2010 criteria?

Rosenkranz SC, Kaulen B, Neuhaus A, Siemonsen S, Köpke S, Daumer M, Stellmann JP, Heesen C.

Eur J Neurol. 2018 Feb;25(2):247-e9. doi: 10.1111/ene.13476. Epub 2017 Dec 2.

PMID:
29024243
26.

Nurse-led immunotreatment DEcision Coaching In people with Multiple Sclerosis (DECIMS) - Feasibility testing, pilot randomised controlled trial and mixed methods process evaluation.

Rahn AC, Köpke S, Backhus I, Kasper J, Anger K, Untiedt B, Alegiani A, Kleiter I, Mühlhauser I, Heesen C.

Int J Nurs Stud. 2018 Feb;78:26-36. doi: 10.1016/j.ijnurstu.2017.08.011. Epub 2017 Aug 26.

PMID:
28982479
27.

Exercise in patients with multiple sclerosis.

Motl RW, Sandroff BM, Kwakkel G, Dalgas U, Feinstein A, Heesen C, Feys P, Thompson AJ.

Lancet Neurol. 2017 Oct;16(10):848-856. doi: 10.1016/S1474-4422(17)30281-8. Epub 2017 Sep 12. Review.

PMID:
28920890
28.

Effect of informed consent on patient characteristics in a stroke thrombolysis trial.

Thomalla G, Boutitie F, Fiebach JB, Simonsen CZ, Nighoghossian N, Pedraza S, Lemmens R, Roy P, Muir KW, Heesen C, Ebinger M, Ford I, Cheng B, Cho TH, Puig J, Thijs V, Endres M, Fiehler J, Gerloff C.

Neurology. 2017 Sep 26;89(13):1400-1407. doi: 10.1212/WNL.0000000000004414. Epub 2017 Aug 25.

29.

Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy.

Giovannetti AM, Giordano A, Pietrolongo E, Confalonieri P, De Luca G, Tortorella C, Trojano M, Messmer Uccelli M, Torri Clerici V, Gitto L, Köpke S, Borreani C, Heesen C, Solari A; ManTra project.

BMJ Open. 2017 Aug 23;7(8):e017254. doi: 10.1136/bmjopen-2017-017254.

30.

Reduced rich-club connectivity is related to disability in primary progressive MS.

Stellmann JP, Hodecker S, Cheng B, Wanke N, Young KL, Hilgetag C, Gerloff C, Heesen C, Thomalla G, Siemonsen S.

Neurol Neuroimmunol Neuroinflamm. 2017 Jul 27;4(5):e375. doi: 10.1212/NXI.0000000000000375. eCollection 2017 Sep.

31.

T1w dark blood imaging improves detection of contrast enhancing lesions in multiple sclerosis.

Thaler C, Schneider T, Sedlacik J, Kutzner D, Stellmann JP, Heesen C, Fiehler J, Siemonsen S.

PLoS One. 2017 Aug 10;12(8):e0183099. doi: 10.1371/journal.pone.0183099. eCollection 2017.

32.

Numeracy of multiple sclerosis patients: A comparison of patients from the PERCEPT study to a German probabilistic sample.

Gaissmaier W, Giese H, Galesic M, Garcia-Retamero R, Kasper J, Kleiter I, Meuth SG, Köpke S, Heesen C.

Patient Educ Couns. 2018 Jan;101(1):74-78. doi: 10.1016/j.pec.2017.07.018. Epub 2017 Jul 17.

PMID:
28764895
33.

Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?

Kjølhede T, Siemonsen S, Wenzel D, Stellmann JP, Ringgaard S, Pedersen BG, Stenager E, Petersen T, Vissing K, Heesen C, Dalgas U.

Mult Scler. 2018 Sep;24(10):1356-1365. doi: 10.1177/1352458517722645. Epub 2017 Jul 28.

PMID:
28752800
34.

No relevant impact of ambient temperature on disability measurements in a large cohort of patients with multiple sclerosis.

Stellmann JP, Young KL, Vettorazzi E, Pöttgen J, Heesen C.

Eur J Neurol. 2017 Jun;24(6):851-857. doi: 10.1111/ene.13301.

PMID:
28544407
35.

Training doctors briefly and in situ to involve their patients in making medical decisions-Preliminary testing of a newly developed module.

Kasper J, Liethmann K, Heesen C, Reissmann DR, Geiger F.

Health Expect. 2017 Dec;20(6):1254-1263. doi: 10.1111/hex.12565. Epub 2017 May 18.

36.

Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients.

Heesen C, Kleiter I, Meuth SG, Krämer J, Kasper J, Köpke S, Gaissmaier W.

J Neurol Sci. 2017 May 15;376:181-190. doi: 10.1016/j.jns.2017.03.001. Epub 2017 Mar 7.

PMID:
28431609
37.

Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?

Krämer J, Tenberge JG, Kleiter I, Gaissmaier W, Ruck T, Heesen C, Meuth SG.

PLoS One. 2017 Apr 13;12(4):e0174858. doi: 10.1371/journal.pone.0174858. eCollection 2017.

38.

Patient education for people with multiple sclerosis-associated fatigue: A systematic review.

Wendebourg MJ, Heesen C, Finlayson M, Meyer B, Pöttgen J, Köpke S.

PLoS One. 2017 Mar 7;12(3):e0173025. doi: 10.1371/journal.pone.0173025. eCollection 2017. Review.

39.

Pattern of gray matter volumes related to retinal thickness and its association with cognitive function in relapsing-remitting MS.

Stellmann JP, Cetin H, Young KL, Hodecker S, Pöttgen J, Bittersohl D, Hassenstein A, Oberwahrenbrock T, Heesen C, Siemonsen S.

Brain Behav. 2016 Dec 20;7(2):e00614. doi: 10.1002/brb3.614. eCollection 2017 Feb.

40.

Reliability of cortical lesion detection on double inversion recovery MRI applying the MAGNIMS-Criteria in multiple sclerosis patients within a 16-months period.

Faizy TD, Thaler C, Ceyrowski T, Broocks G, Treffler N, Sedlacik J, Stürner K, Stellmann JP, Heesen C, Fiehler J, Siemonsen S.

PLoS One. 2017 Feb 24;12(2):e0172923. doi: 10.1371/journal.pone.0172923. eCollection 2017.

41.

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS.

Hodecker SC, Stürner KH, Becker V, Elias-Hamp B, Holst B, Friese MA, Heesen C.

Neurol Neuroimmunol Neuroinflamm. 2017 Feb 8;4(2):e325. doi: 10.1212/NXI.0000000000000325. eCollection 2017 Mar. No abstract available.

42.

Ruxolitinib treatment in a patient with neuromyelitis optica: A case report.

Hodecker SC, Stellmann JP, Rosenkranz SC, Young K, Holst B, Friese MA, Heesen C.

Neurol Neuroimmunol Neuroinflamm. 2017 Feb 3;4(2):e328. doi: 10.1212/NXI.0000000000000328. eCollection 2017 Mar. No abstract available.

43.

T1 Recovery Is Predominantly Found in Black Holes and Is Associated with Clinical Improvement in Patients with Multiple Sclerosis.

Thaler C, Faizy TD, Sedlacik J, Holst B, Stürner K, Heesen C, Stellmann JP, Fiehler J, Siemonsen S.

AJNR Am J Neuroradiol. 2017 Feb;38(2):264-269. doi: 10.3174/ajnr.A5004. Epub 2016 Nov 10.

44.

A new graphical format to communicate treatment effects to patients-A web-based randomized controlled trial.

Kasper J, van de Roemer A, Pöttgen J, Rahn A, Backhus I, Bay Y, Köpke S, Heesen C.

Health Expect. 2017 Aug;20(4):797-804. doi: 10.1111/hex.12522. Epub 2016 Dec 16.

45.

Dietary Interventions in Multiple Sclerosis: Development and Pilot-Testing of an Evidence Based Patient Education Program.

Riemann-Lorenz K, Eilers M, von Geldern G, Schulz KH, Köpke S, Heesen C.

PLoS One. 2016 Oct 20;11(10):e0165246. doi: 10.1371/journal.pone.0165246. eCollection 2016.

46.

Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis.

Briken S, Rosenkranz SC, Keminer O, Patra S, Ketels G, Heesen C, Hellweg R, Pless O, Schulz KH, Gold SM.

J Neuroimmunol. 2016 Oct 15;299:53-58. doi: 10.1016/j.jneuroim.2016.08.007. Epub 2016 Aug 5.

PMID:
27725121
47.

Disease Activity and Conversion into Multiple Sclerosis after Optic Neuritis Is Treated with Erythropoietin.

Sühs KW, Papanagiotou P, Hein K, Pul R, Scholz K, Heesen C, Diem R.

Int J Mol Sci. 2016 Sep 30;17(10). pii: E1666.

48.

Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting.

von Gumberz J, Mahmoudi M, Young K, Schippling S, Martin R, Heesen C, Siemonsen S, Stellmann JP.

PeerJ. 2016 Sep 20;4:e2442. doi: 10.7717/peerj.2442. eCollection 2016.

49.

Comprehension of confidence intervals - development and piloting of patient information materials for people with multiple sclerosis: qualitative study and pilot randomised controlled trial.

Rahn AC, Backhus I, Fuest F, Riemann-Lorenz K, Köpke S, van de Roemer A, Mühlhauser I, Heesen C.

BMC Med Inform Decis Mak. 2016 Sep 20;16(1):122. doi: 10.1186/s12911-016-0362-8.

50.

Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes.

Stellmann JP, Jlussi M, Neuhaus A, Lederer C, Daumer M, Heesen C.

J Neurol Sci. 2016 Sep 15;368:318-25. doi: 10.1016/j.jns.2016.07.051. Epub 2016 Jul 25.

PMID:
27538657

Supplemental Content

Loading ...
Support Center